40
4
58
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36771 |
11-deoxy Prostaglandin F1α
11-deoxy Prostaglandin F1α |
||
11-deoxy PGF1α is a synthetic analog of PGF1α. In whole animal studies, a dose of 32 mg/kg inhibited gastric acid secretion by 35%. 11-deoxy PGF1α is also known to cause rat uterine contractions at a dose 0.3 times that of PGF1α. It also exhibits vasopressor and bronchoconstrictor activities at about half the potency of PGF2α in guinea pigs. | |||
T36772 |
11-deoxy Prostaglandin F1β
11-deoxy Prostaglandin F1β |
||
11-deoxy PGF1β is a synthetic analog of PGF1β. In contrast to PGF2α and PGF1α, 11-deoxy PGF1β exhibits vasodepressor and bronchodilator activities in guinea pigs at a dose of 500 μg/kg. | |||
T77745 |
N6F11
|
GPX | oxidation-reduction |
N6F11是一种新型且具有选择性和有效性的铁死亡诱导剂,具有抗癌抗肿瘤活性,通过与癌细胞中的TRIM25结合从而促进GPX4降解。N6F11 可用于研究胰腺癌。 | |||
T34278 |
Redaporfin
F 2BMet,F2BMet,F-2BMet,LUZ11,LUZ 11,LUZ-11 |
||
Redaporfin, also known as F-2BMet or LUZ-11, is a photosensitizer for Photodynamic Therapy (PDT) of cancer. Redaporfin showed a high efficacy in the treatment of male BALB/c mice with subcutaneously implanted colon (CT26) tumours. Vascular-PDT with 1.5 mg | |||
T20814 |
Loratadine specified impurity F
11-Fluoro dihydroloratadine |
||
Loratadine specified impurity F is a fluorinated analog of Loratadine. | |||
T72501 |
CYP4A11/CYP4F2-IN-1
|
P450 | Metabolism |
CYP4A11/CYP4F2-IN-1 是一种高效的小分子细胞色素 P450 (CYP) 4A11 和 CYP4F2 抑制剂,对P450 (CYP) 4A11 的 IC50 值为 19 nM,对 CYP4F2 的 IC50 值为 17 nM。CYP4A11/CYP4F2-IN-1 可用于研究肾脏疾病和心脑血管疾病。 | |||
T67916 |
CYP4A11/CYP4F2-IN-2
|
P450 | Metabolism |
CYP4A11/CYP4F2-IN-2 是一种有效的和具有口服活性的细胞色素 P450 (CYP) 4A11 和 CYP4F2 的双重抑制剂,IC50 值分别为 140 nM 和 40 nM。CYP4A11/CYP4F2-IN-2可从肝脏和肾脏中提取, 具有治疗肾脏疾病的潜力。 | |||
T36455 |
11β-Prostaglandin F2α
11β-Prostaglandin F2α |
||
11β-Prostaglandin F2α 是一种由 AKR1C3 催化的生物活性代谢物,可刺激前列腺素 F 受体并诱导乳腺癌中的 slug 表达。11β-Prostaglandin F2α 也是存在于尿液中的内源代谢物。 | |||
T79883 |
9-Chloromethyl-10-hydroxy-11-F-Camptothecin
|
Topoisomerase | DNA Damage/DNA Repair |
9-Chloromethyl-10-Hydroxy-11-F-Camptothecin是一款喜树碱类衍生化合物,具有DNA拓扑异构酶I (Topo I)抑制活性,应用于癌症治疗的研究领域。 | |||
T65432 |
10,11-Dihydro-11-oxodibenzo[b,f][1,4]thiazepine
|
||
10,11-Dihydro-11-oxodibenzo[b,f][1,4]thiazepine 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T65432,CAS号为 3159-07-7。 | |||
T37275 |
2,3-dinor-11β-Prostaglandin F2α
2,3-dinor-11β-Prostaglandin F2α |
||
2,3-dinor-11β-Prostaglandin F2α (2,3-dinor-11β-PGF2α) was recovered from the urine of both normal monkeys and humans when infused with radiolabeled PGD2, where it represented approximately 1% and 4% of the infused radiolabeled dose, respectively. 2,3-dinor-11β-PGF2α has also been recovered from the urine of mastocytosis patients, where it is excreted in large amounts. In human asthmatic patients, 2,3-dinor-11β-PGF2α represents about 40% (as determined by GC/MS) of the immunoreactive 11β-PGF2α wh... | |||
T65682 |
11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepine dihydrochloride
|
||
11-(1-Piperazinyl)-dibenzo[b,f][1,4]thiazepine dihydrochloride 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T65682,CAS号为 111974-74-4。 | |||
T83468 |
10NH2-11F-Camptothecin
|
||
10NH2-11F-Camptothecin 是抗癌活性的抗体-活性分子偶联物(ADC),用于癌症疾病的研究。 | |||
T83244 |
7Ethanol-10NH2-11F-Camptothecin
|
||
7Ethanol-10NH2-11F-Camptothecin 是一抗体-活性分子偶联物(ADC),具有抑制肿瘤生长的功能,适用于癌症研究。 | |||
T75134 | MC-GGFG-AM-(10Me-11F-Camptothecin) | ||
MC-GGFG-AM-(10Me-11F-Camptothecin) 是ZW251合成的Linker-Payload偶联物。ZW251是靶向人GPC3的抗体-活性分子偶联物(ADC),包括人源化IgG1抗体、喜树碱(camptothecin)类的扑异构酶1抑制剂ZD06519及连接子(马来酰亚胺锚定和甘酰甘酰苯丙酰甘氨酸(GGFG)-氨基甲基(AM)可切割连接体)。该药物对人和食蟹猴GPC3具高亲和力,在表达GPC3的HCC细胞系中快速内化并可对GPC3阴性癌细胞进行旁观者介导杀伤。 | |||
T81833 |
MC-GGFG-AM-(10NH2-11F-Camptothecin)
|
||
MC-GGFG-AM-(10NH2-11F-Camptothecin) 是一种ADC,其通过pH敏感的可水解连接物与Trop-2针对性抗体sacituzumab偶联,展现出针对癌症的活性,适用于癌症研究领域。 | |||
T81834 |
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)
|
||
MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) (compound 141) 为ADC用途的drug-linker conjugate,其结构包括7ethanol-10NH2-11F-Camptothecin 与蛋白酶可降解(cleavable)的MC-GGFG通过化学键连接形成。 | |||
T67397 | (11aS)-1,11-Bis(diphenylphosphino)dibenzo[d,f][1,3]dioxepine | ||
(11aS)-1,11-Bis(diphenylphosphino)dibenzo[d,f][1,3]dioxepine 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T67397。 | |||
T67396 |
(11aR)-1,11-Bis(diphenylphosphino)dibenzo[d,f][1,3]dioxepine
|
||
(11aR)-1,11-Bis(diphenylphosphino)dibenzo[d,f][1,3]dioxepine 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T67396。 | |||
T64437 | 5-(11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl-5H-dibenz[b,f]azepine | ||
5-(11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl-5H-dibenz[b,f]azepine 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T64437。 | |||
T64639 | (11AS)-5-(4,5,6,7-tetrahydrodiindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-12-yl)-5H-dibenzo[b,f]azepine | ||
(11AS)-5-(4,5,6,7-tetrahydrodiindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-12-yl)-5H-dibenzo[b,f]azepine 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T64639。 | |||
T64513 |
(11aR)-5-(4,5,6,7-Tetrahydrodiindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-12-yl)-5H-dibenzo[b,f]azepine
|
||
(11aR)-5-(4,5,6,7-Tetrahydrodiindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-12-yl)-5H-dibenzo[b,f]azepine 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T64513。 | |||
T66996 | (4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid | ||
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T66996,CAS号为 104239-97-6。 | |||
T67601 |
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid
|
||
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T67601,CAS号为 103335-55-3。 | |||
T65298 |
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-Methyl 4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylate
|
||
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-Methyl 4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylate 是一种有用的有机化合物,可用于生命科学领域的相关研究,其产品编号为 T65298。 | |||
T10870L |
CP-547632
|
VEGFR; FGFR; PDGFR; BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
CP-547632是一种可口服且具有有效性、ATP 竞争性的 血管内皮生长因子受体2(VEGFR-2 )和 碱性成纤维细胞生长因子(FGF)激酶F 双重抑制剂,IC50 分别为 11 nM 和 9 nM。CP-547632具有选择性,对 VEGFR2 和 bFGF 的选择性高于 EGFR,PDGFRβ 和相关的酪氨酸激酶 (TKs) 。 CP-547632具有抗肿瘤活性。 | |||
T39760 |
BAY-6672
|
||
BAY-6672 is a highly potent and selective antagonist of the human Prostaglandin F (FP) receptor, displaying an IC 50 value of 11 nM. | |||
T74213 |
BAY-6672 hydrochloride
|
||
BAY-6672 hydrochloride为具有高效性和选择性的人前列腺素F(FP)受体拮抗剂,IC50为11 nM。 | |||
T65692 |
Boc-D-Phe(3-F)-OH
|
||
Boc-D-Phe(3-F)-OH 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T65692,CAS号为 114873-11-9。 | |||
T67591 |
5-Acetyl-3-chloro-10,11-dihydro-5H-dibenz[b,f]azepine
|
||
5-Acetyl-3-chloro-10,11-dihydro-5H-dibenz[b,f]azepine 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T67591,CAS号为 25961-11-9。 | |||
T35485 |
6-Prenylindole
|
||
6-Prenylindole is a bacterial metabolite that has been found in Streptomyces and has antifungal and antimalarial properties.1 It is active against A. brassicicola strain TP-F0423 and F. oxysporum f. sp. tulipae TU-4-2 (15 and 30 μg/disc in the paper disc assay), and also drug-resistant P. falciparum strain K1 (IC50 = 21 μg/ml).2 |1. Sasaki, T., Igarashi, Y., Ogawa, M., et al. Identification of 6-prenylindole as an antifungal metabolite of Streptomyces sp. TP-A0595 and synthesis and bioactivity o... | |||
T83733 |
TIP39 (human, bovine) TFA
Tuberoinfundibular Peptide of 39 Residues |
||
TIP39作为一种神经肽及甲状旁腺激素受体2型(PTH2R)激动剂,在表达重组人或大鼠PTH2R的COS-7细胞中诱导cAMP积累(EC50分别为0.5和0.8 nM),以及在内源性表达PTH2R的F-11细胞中(EC50 = 1.15 nM)。在CFK2大鼠软骨细胞中,TIP39 (1 nM)诱导细胞周期在G0/G1阶段停滞,并减少软骨分化的主要调控因子Sox9的表达。此外,TIP39 (100 pmol/动物)在小鼠强迫游泳测试中减少了不动时间。 | |||
T35854 |
9(Z),11(E)-Conjugated Linoleic Acid (sodium salt)
|
||
9(Z),11(E)-Conjugated linoleic acid is an isomer of linoleic acid that has been found in beef and milk fat.1It binds to peroxisome proliferator-activated receptor α (PPARα; IC50= 140 nM) and activates the receptor in a reporter assay using COS-1 cells expressing mouse PPARα when used at a concentration of 100 μM.29(Z),11(E)-Conjugated linoleic acid inhibits TNF-α-inducedGLUT4expression and increases insulin-stimulated glucose transport in 3T3-L1 adipocytes.3Dietary administration of 9(Z)11(E)-co... | |||
T38353 |
Pyrenocine A
|
||
Pyrenocine A is a fungal metabolite that has been found inP. terrestrisand has diverse biological activities.1It inhibits the asexual spore germination of the plant pathogenic fungiF. oxysporum,F. solani,M. hiemalis, andR. stolonifer(EC50s = 14, 20, 20, and 25 μg/ml, respectively). Pyrenocine A is active againstB. subtilis,S. aureus, andE. coli(IC50s = 30, 45, and 200 μg/ml, respectively). It inhibits onion seedling elongation (EC50= 4 μg/ml). Pyrenocine A is also a phytotoxin that inhibits lett... | |||
T36892 | 4'-Acetyl Chrysomycin A | ||
4'-Acetyl chrysomycin A is a bacterial metabolite and derivative of chrysomycin A that has been found inStreptomycesand has antibacterial and anticancer activities.1It is active against strains of methicillin-resistantS. aureus(MRSA) and vancomycin-resistant strains ofE. faecalisandE. faecium(MICs = 0.5-2 μg/ml for all). 4'-Acetyl chrysomycin A is cytotoxic against a panel of human cancer cell lines, including doxorubicin-sensitive or -resistant cells (IC50s = 0.085-0.26 and 3.4-16 ng/ml, respec... | |||
T35978 | Benastatin A | ||
Benastatin A is a polyketide synthase-derived benastatin that has been found inStreptomycesand has diverse biological activities.1,2,3It inhibits glutathione S-transferase (GST; Ki= 5 μM for the rat liver enzyme).2Benastatin A is active against several bacteria, including methicillin-resistantS. aureus(MRSA; MIC = 3.12 μg/ml). It induces apoptosis and cell cycle arrest at the G1/G0phase in Colon 26 mouse colon cancer cells when used at concentrations of 20 and 16 μM, respectively.3 1.Xu, Z., Sch... | |||
T36176 |
AMK (hydrochloride)
|
||
AMK is an active metabolite of the neurohormone melatonin .1,2,3,4It is formed from melatoninviathe metabolic intermediate AFMK that is then deformylated by catalase or formamidase.5,6AMK scavenges singlet oxygenin vitrowhen used at a concentration of 200 μM.1It inhibits the epinephrine- and arachidonic acid-induced production of prostaglandin E2and PGD2in ovine seminal vesicle microsomes in a concentration- and time-dependent manner, as well as LPS-induced increases in COX-2 levels in RAW 264.7... | |||
T37605 |
D-DOPA
|
||
D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p... | |||
T36629 | Givinostat | ||
Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF-2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 1... | |||
T38174 | Mpro inhibitor N3 hemihydrate | ||
Mpro inhibitor N3 hemihydrate is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 of 16.77 μM for SARS-CoV-2. Mpro inhibitor N3 hemihydrate specifically inhibits Mpro from multiple coronaviruses, including SARS-CoV and MERS-CoV. Mpro inhibitor N3 hemihydrate displays inhibition against HCoV-229E, FIPV, and MHV-A59 with individual IC50 of 4.0 μM, 8.8 μM, and 2.7 μM, respectively[1][2]. Mpro inhibitor N3 hemihydrate (0-0.64 μM) is able to penetrate cells to inhibit the replication of IBV viruses... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3920 |
Pseudoginsenoside F11
Ginsenoside A1,拟人参皂苷 F11,拟人参皂苷F11 |
Others; Endogenous Metabolite | Metabolism; Others |
Pseudoginsenoside F11 (Ginsenoside A1) 从人参根和叶中分离得到。PF11在一系列心血管和中枢神经系统疾病中具有广泛的保护作用。 | |||
TN1186 |
11(α)-Methoxysaikosaponin F
11 α-甲氧基柴胡皂苷 F,11alpha-Methoxysaikosaponin F,11(Α)甲氧基柴胡皂苷F |
Others | Others |
11alpha-Methoxysaikosaponin F is a natural product | |||
T37219 |
N-Palmitoyl Glycine
|
||
The acyl amides are a family of endogenous lipids that act as potent modulators of pain and inflammation. The best characterized members of this family are the arachidonoyl amides, which includes N-arachidonoyl ethanolamide (AEA; anandamide). N-palmitoyl glycine (PalGly) contains an 18-carbon saturated fatty acid that is amide-linked to glycine and is structurally similar to the phospholipid-derived N-acyl ethanolamines. Endogenously produced in rat skin and spinal cord, PalGly is present in 100... | |||
T36000 |
3-Hydroxyterphenyllin
|
||
3-Hydroxyterphenyllin is a p-terphenyl fungal metabolite originally isolated from A. candidus that has diverse biological activities, including antioxidant, antiproliferative, antibacterial, and antiviral properties.1,2,3,4 It has a 96% scavenging effect on 2,2-diphenyl-1-picrylhydrazyl radicals when used at a concentration of 100 μg/ml.2 3-Hydroxyterphenyllin inhibits the growth of HeLa cervical, A549 lung, and HepG2 liver cancer cells (IC50s = 23, 36, and 32 μM, respectively), as well as methi... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01104 |
Coagulation factor XI/F11 Protein, Human, Recombinant (His)
coagulation factor 11,coagulation f |
Human | HEK293 Cells |
Factor XI (plasma thromboplastin antecedent) is a plasma glycoprotein, and a zymogen acting as a serine protease which participates in blood coagulation as a catalyst in the conversion of factor IX to factor IXa in the presence of calcium ions. It is an unusual dimeric protease, with structural features that distinguish it from vitamin K-dependent coagulation proteases. The factor XI is synthesized in the liver as a single polypeptide chain with a molecular weight estimated between 125 ~160 kDa ... | |||
TMPY-00414 |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His)
ILT-11,CD85F,LIR-9,LIR9,LILRB7,CD85,ILT |
Human | HEK293 Cells |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.7 kDa and the accession number is A6NI73-1. | |||
TMPK-01271 |
Coagulation factor XI Protein, Cynomolgus, Recombinant (His)
F11,PTA,FXI,Coagulation f |
Cynomolgus | HEK293 Cells |
Factor XI (FXI) is the zymogen of a plasma protease (FXIa) that contributes to hemostasis by activating factor IX (FIX). In the original cascade model of coagulation, FXI is converted to FXIa by factor XIIa (FXIIa), a component, along with prekallikrein and high-molecular-weight kininogen (HK), of the plasma kallikrein-kinin system (KKS). | |||
TMPY-03069 |
LILRA5/CD85f/ILT11 Protein, Rat, Recombinant (His)
leukocyte immunoglobulin-like receptor, subfamily A... |
Rat | HEK293 Cells |
LILRA5/CD85f/ILT11 Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 27.2 kDa and the accession number is D4A6Y0. | |||
TMPY-03097 |
LILRA5/CD85f/ILT11 Protein, Rat, Recombinant (hFc)
leukocyte immunoglobulin-like receptor, subfamily A... |
Rat | HEK293 Cells |
LILRA5/CD85f/ILT11 Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 52.8 kDa and the accession number is D4A6Y0. | |||
TMPY-04309 |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (hFc)
LILRB7,LIR9,leukocyte immunoglobulin-like receptor, subf... |
Human | HEK293 Cells |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 52 kDa and the accession number is A6NI73-1. | |||
TMPK-00185 |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His & Avi)
ILT11CD85f,LIR-9,ILT11,LILRA5,CD8... |
Human | HEK293 Cells |
The leukocyte immunoglobulin-like receptors (LILR) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIRs). Human LILRA5, also known as ILT11, LIR-9, and CD85f, consists of a 227 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 10 aa cytoplasmic tail. LILRA5 may play a role in triggering innate immune responses. Does not seem to play a role for any class I MHC a... | |||
TMPY-05230 |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His), Biotinylated
CD85,ILT11,LIR9,ILT-11,CD85F,LIR-... |
Human | HEK293 Cells |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 26.7 kDa and the accession number is A6NI73-1. | |||
TMPY-05605 |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His & Avi), Biotinylated
leukocyte immunoglobulin-like receptor, subfamily A... |
Human | HEK293 Cells |
LILRA5/CD85f/ILT11 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 28.5 kDa and the accession number is A6NI73-1. | |||
TMPJ-01254 |
Siglec-F Protein, Mouse, Recombinant (His)
sialic acid binding Ig like lectin 8,SAF2,SIGLEC-8,... |
Mouse | HEK293 Cells |
Siglec 5 to 11 share a high degree of sequence similarity with CD33/Siglec-3 both in their extracellular and intracellular regions. They are collectively referred to as CD33-related Siglecs. One remarkable feature of the CD33-related Siglecs is their differential expression pattern within the hematopoietic system. This fact, together with the presence of two conserved immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasmic tails, suggests that CD33-related Siglecs are involv... | |||
TMPY-02005 |
Mucin-1/MUC1 Protein, Human, Recombinant (hFc)
PEM,ADMCKD1,CA15-3,CD227,MCD,mucin 1, cell surface ... |
Human | HEK293 Cells |
Mucin-1/MUC1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 42 kDa and the accession number is P15941-11. | |||
TMPY-04340 |
Mucin-1/MUC1 Protein, Human, Recombinant
mucin 1, cell surface associated,MUC-1/SEC,PEM,MUC1... |
Human | HEK293 Cells |
Mucin-1/MUC1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 15.4 kDa and the accession number is P15941-11. | |||
TMPJ-00155 |
Mucin-1/MUC1 Protein, Human, Recombinant (hFc&Avi), Biotinylated
Polymorphic epithelial mucin,KL-6,Cancer antigen 15-3,PEMT,P... |
Human | HEK293 Cells |
Mucin-1, is a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. MUC-1 exclusively located in the apical domain of the plasma membrane ... | |||
TMPY-02871 |
Mucin-1/MUC1 Protein, Human, Recombinant (mFc)
mucin 1, cell surface associated,ADMCKD1,EMA,MCKD1,... |
Human | HEK293 Cells |
Mucin-1/MUC1 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 41 kDa and the accession number is P15941-11. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01405 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-RAS2A,K-RAS2B,GTPa... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01428 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RALD,KI-RAS,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01462 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01443 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,KRAS2,NS3... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01460 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras,K-RAS2B,C-K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01503 |
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi)
Macropain chain 7,LMP-2,RING12,LMP2,RMF,MHC,PSMB9,P... |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01427 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CF |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras,RALD,MHC... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4B,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01479 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,K-RAS4A,CF |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase Kras,KRAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01461 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-RAS2A,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-RAS2A,K-RAS2B,RALD,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4B,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RAS2B,CFC2,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RASK2,C-K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01433 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RAS4A,C... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01402 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
KRAS1,NS,CFC2,K-RAS4B,RASK2,K-Ras 2,KI-RAS,GTPase K... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01430 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS,MHC,K-RAS2B,K-RAS4A,KRAS1... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01432 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01440 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CF... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01528 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K-Ras 2,KI-RAS,K-RA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01465 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS2A,CFC2,KRAS,GTPase Kras,K-RAS2B,K-Ras 2,K... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01438 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
RASK2,KRAS2,KRAS1,MHC,C-K-RAS,KI-RAS,K-RAS4B,RALD,K-RAS4A,NS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01498 |
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Tetramer Protein, Human, MHC (His & Avi)
Proteasome chain 7,MHC,RING12,RMF,LMP2,LMP-2,PSMB9,... |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01507 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)
K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,NS,MHC,NS3,K-RAS4A... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01400 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS1,RALD,K-RAS2A,K-RAS2B,K-RAS4A,MHC,RASK2,KRAS,GTPase ... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01536 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase Kras,K-Ras 2,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01464 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-RAS2B,MHC,KRAS2,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
------------------------ 更多 ------------------------ |